Merit Medical Systems, Inc. (MMSI)
Juste valeurFondamental
70
Prix
$86.23
Capitalisation boursière
$5.15B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 septembre 2026 with claude-haiku-4-5 — shared with all users
BD's interventional and vascular access lines compete with Merit for the same hospital purchasing contracts on catheters, ports, drainage and biopsy products.
Boston Scientific sells competing peripheral intervention, embolization and endoscopy devices, the three areas where Merit generates most of its revenue.
Merit names Teleflex first among its rivals in both peripheral and cardiac intervention, where the two sell overlapping catheters, introducers and vascular access devices to the same interventional radiology and cardiology labs.
Cook Medical, privately held, is the one competitor Merit names in every product area — peripheral intervention, cardiac intervention, oncology and endoscopy — with a directly comparable catalogue of interventional catheters, guidewires and biopsy devices.
Medtronic competes with Merit in peripheral and cardiac intervention and, through its spine business, for the OEM and implant components Merit also supplies.
Terumo is named by Merit as a cardiac intervention competitor, selling rival radial access sheaths, guidewires and inflation devices to the same catheter labs, with particular strength in Japan and Europe.
Bilan & Liquidités
Chiffre d'affaires
$1.58B
12 derniers mois (au 30/06/2026)
Résultat net
$146M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$216M
Capitaux propres totaux
$1.58B
Passif total
$1.10B
Ratio de liquidité général
4.20
Couverture des intérêts
6.34
Dette/EBITDA
2.66
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$74.75
Prix actuel
$86.23
Marge de sécurité
-15.4%
Fourchette de juste valeur
$48.58 - $100.91
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
35.49
ROE
8.1%
Ratio P/B
3.07
P/FCF
25.34
Marge brute
49.5%
ROIC
6.1%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
6.1%
WACC
7.3%
ROIC − WACC
-1.1 pp
Le ROIC est inférieur au coût du capital — l'entreprise détruit de la valeur pour chaque dollar investi.
Critères d'analyse fondamentale
Réussi (21)
- EPS shows upward trend
- EPS CAGR 7.91%
- Price CAGR 12.63%
- ROIC 6.1%
- Gross Margin 49.5%
- P/FCF 25.34
- Debt/Equity ratio
- Operating Margin 12.8%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 9.1%
- Revenue Growth 5Y 9.5%
- Analyst Consensus 82% Buy
- Earnings Surprise avg 11.9%
- Earnings Quality (OCF/NI) 1.95
- Share Dilution 1.7%
- Net Margin Trend 9.2% vs 8.3%
- Piotroski F-Score 7/9
Échoué (5)
- P/B Ratio 3.07
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
Indisponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Le nombre d'actions est stable
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Ms. Martha Goldberg Aronson | President, CEO & Director | 58 |
| Mr. Raul Parra Jr., CPA | CFO & Treasurer | 46 |
| Mr. Brian G. Lloyd J.D. | Chief Legal Officer & Corporate Secretary | 64 |
| Mr. Michel J. Voigt | Chief Human Resources Officer | 52 |
| Mr. Neil W. Peterson | Senior Advisor | 59 |
| Mr. Jason Treft | Chief Information Officer | - |
| Ms. Sarah Comstock | Vice President of Global Communications | - |
| Mr. John Knorpp | Chief Regulatory Affairs Officer | - |
| Mr. Ricardo Alvarez | Managing Director of Operation Merit Medical Tijuana | - |
| Mr. Mark Butler | Executive Vice President of Merit Medical EMEA | - |
Risque d'audit
2
Risque du conseil
2
Risque de rémunération
1
Risque droits des actionnaires
4
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-24
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-07-30
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-08-20
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for MMSI, sourced from Markets Gazette.